Ozempic Alternatives: What Researchers Are Studying Instead

Semaglutide, the active compound in Ozempic and Wegovy, became the reference point for GLP-1 peptide research when its clinical results were published. But the research landscape has moved significantly since then. For researchers studying metabolic peptides, multiple alternatives now exist with distinct advantages depending on the research question.

Within the GLP-1 Class: Tirzepatide

Tirzepatide is the most direct alternative to semaglutide for GLP-1 research. It adds GIP receptor agonism to the GLP-1 mechanism, producing higher average weight loss in trials (approximately 20% vs. 15% for semaglutide). For researchers studying appetite regulation and metabolic outcomes, tirzepatide provides a dual-receptor model that semaglutide cannot. It has FDA approval and strong Phase 3 data, making it among the best characterized compounds in the class.

Within the GLP-1 Class: Retatrutide

Retatrutide adds glucagon receptor agonism on top of the GLP-1 and GIP mechanisms in tirzepatide. Phase 2 data shows approximately 24% average weight loss over 48 weeks, the highest figure reported for any compound in this class. It is still in Phase 3 trials as of 2026 and does not yet have regulatory approval. For researchers interested in the triple-agonist mechanism or studying energy expenditure alongside appetite regulation, retatrutide represents the cutting edge of this class.

Outside the GLP-1 Class: AOD 9604

AOD 9604 is a fragment of human growth hormone studied for its fat-burning properties. It operates through a completely different mechanism than GLP-1: it directly stimulates lipolysis at the cellular level without affecting appetite or gut motility. For researchers who need to study fat metabolism without the GI effects associated with GLP-1 compounds, AOD 9604 offers a mechanistically distinct alternative. It has a favorable safety profile from human trials and GRAS status from TGA.

Outside the GLP-1 Class: Growth Hormone Secretagogues

CJC-1295, ipamorelin, and sermorelin affect body composition by stimulating growth hormone release, which in turn influences fat metabolism and lean mass. These compounds work over longer timescales than GLP-1 peptides and through completely different pathways. They are studied for body composition broadly rather than acute weight loss specifically. For researchers interested in hormonal regulation of metabolism, this class offers a different entry point.

Why Researchers Explore Alternatives

Several factors drive researchers toward alternatives to semaglutide. The first is mechanism: different research questions require different receptor profiles, and studying the GIP and glucagon pathways requires compounds that activate them. The second is tolerability: the GI side effect profile of semaglutide leads some researchers to study compounds with different side effect profiles. The third is timeline: semaglutide has been in clinical use for years, and newer compounds offer the opportunity to study novel mechanisms before they are fully characterized.

What the Research Gap Is

The major unanswered question across all GLP-1 alternatives is long-term safety and efficacy after the trial period ends. Semaglutide has the most long-term data, though even that extends only to approximately five years. Tirzepatide, retatrutide, and the non-GLP-1 alternatives have shorter data histories. Researchers studying these compounds should weight the richness of efficacy data against the relative immaturity of long-term safety data.

Werner Science carries semaglutide, tirzepatide, retatrutide, AOD 9604, and related research peptides. Browse their catalog at wernerscience.com/?ref=bwmucbwp and use code SAVE10 for a discount on your order.